Metabolism News and Research

Latest Metabolism News and Research

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

Metabolic profile reveals need for gender-specific therapies

Analyses of the metabolic profile of blood serum reveal significant differences between men and women. From their tests, scientists at the Helmholtz Zentrum München have concluded that there is a need for gender-specific therapies. The study was financed by the German Centre for Diabetes Research and was published in the current edition of the internationally renowned peer-reviewjournal PLoS Genetics.

12 Aug 2011

Interleukin Genetics second quarter total revenue increases to $0.8 million

Interleukin Genetics, Inc. today announced financial and operational results for the second quarter ended June 30, 2011.

12 Aug 2011

Pregnant women lack enough vitamin D despite use of prenatal supplements

Pregnant women taking prenatal supplements may not be getting enough vitamin D, shows a new Vancouver-based study led by the Child & Family Research Institute at BC Children's Hospital that was published in the Canadian Journal of Public Health.

12 Aug 2011

Study finds increase in amount of brown fat among lean children

Researchers at Joslin Diabetes Center and Children's Hospital Boston have shown that a type of "good" fat known as brown fat occurs in varying amounts in children - increasing until puberty and then declining -- and is most active in leaner children.

12 Aug 2011

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.

11 Aug 2011

Study: AAKG supplementation has no significant impact on increased blood flow

A Baylor University study has found that a popular nutritional supplement that is marketed to lead to greater muscle strength through increasing blood flow to the muscle does not increase blood flow as claimed on the bottle.

11 Aug 2011

Scientists identify 29 new genetic variants linked to multiple sclerosis

Scientists have identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of a very debilitating neurological disease. Many of the genes -implicated in the study are relevant to the immune system, shedding light onto the immunological pathways that underlie the development of multiple sclerosis.

11 Aug 2011

Vitamin D, UVB may help prevent dental caries

Large geographical variations in dental health and tooth loss among U.S. adolescents and young adults have been reported since the mid-1800s. The first study finding a north-south gradient in dental caries was a report of men rejected from the draft for the Civil War for lost teeth, from 8 per 1000 men in Kentucky to 25 in New England.

10 Aug 2011

Pfizer, UC San Diego sign research agreement to drive innovation in drug discovery

In an innovative collaboration designed to speed the process of drug discovery, Pfizer, Inc. and the University of California, San Diego Health Sciences announced today that UC San Diego has joined the ranks of other top-tier life science research institutions across the country as part of Pfizer's Centers for Therapeutic Innovation.

9 Aug 2011

New Acromegaly clinical practice guidelines

Today the American Association of Clinical Endocrinologists (AACE) released updated Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly.

9 Aug 2011

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress.

8 Aug 2011

New finding about cell metabolism may have implications for neurodegenerative disorders

Cells are the building blocks of the human body. They are a focus of scientific study, because when things go wrong at the cellular and molecular level the consequences for human health are often significant.

8 Aug 2011

Researchers discover lack of oxygen in the lungs after mold invasion

Researchers led by Montana State University have found a surprising condition that occurs in the lungs after an invasion of a common mold that can cause deadly infections in humans.

6 Aug 2011

New analytical method can develop specific drugs against parasites, bacteria

A team led by Professor Malcolm McConville from the Bio21 Institute, University of Melbourne developed a new analytical method which can be used for many infectious parasites and bacteria.

6 Aug 2011

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Simcyp Limited is pleased to announce significant additions to its flagship simulator in line with priorities established by the Simcyp Consortium of global pharmaceutical companies.

6 Aug 2011

Insulin pumps and other medical devices ‘hackable’

A diabetic security researcher has identified flaws that could allow an attacker to remotely control insulin pumps and alter the readouts of blood-sugar monitors. As a result, diabetics could get too much or too little insulin, a hormone they need for proper metabolism.

5 Aug 2011

New polymer effectively captures nicotine molecules and analogues

Newly synthesized polymer, fitted with molecular pincers of carefully tailored structure, effectively captures nicotine molecules and its analogues.

5 Aug 2011

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin.

5 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011